Wells Fargo & Company Kezar Life Sciences, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KZR
# of Institutions
83Shares Held
39.6MCall Options Held
3.2KPut Options Held
700-
Suvretta Capital Management, LLC New York, NY7.17MShares$4.01 Million0.18% of portfolio
-
Avidity Partners Management LP Dallas, TX5.03MShares$2.81 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.74MShares$1.54 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L32.05MShares$1.15 Million0.18% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.93MShares$1.08 Million0.03% of portfolio
About Kezar Life Sciences, Inc.
- Ticker KZR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,369,504
- Market Cap $38.3M
- Description
- Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...